Half billion dollar investment in West Coast biotech prospects

15 December 2020

Californian investment group Westlake Village BioPartners has launched two new funds totaling $500 million, with the goal of promoting promising firms with innovative technologies.

The life sciences-focused company, which established its first fund in 2018, has since invested in or incubated 11 companies, mainly in the local Los Angeles area.

Co-founder Sean Harper said: “We are rapidly moving into what we at Westlake call ‘The Golden Age of Biotechnology’ where the speed of innovation and discoveries is accelerating exponentially.”

He added: “This exponential growth is presenting many opportunities to develop new medicines, and these additional funds will allow us to harness that innovation to develop therapies for serious diseases.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK